J&J divests from some of its incubator sites
Johnson & Johnson is scaling back its network of lab and office space meant to support early-stage startups, winding down locations in Toronto, Houston and DC. The company is divesting from some...
View ArticleAltos Labs hires a new medical chief with mTOR experience, Novartis chops
Altos Labs, the secretive anti-aging company with billions of dollars in funding, has a new chief medical officer to steer its clinical development. Joan Mannick joins from Tornado Therapeutics, a...
View ArticleVertex’s top scientist Altshuler to retire, next-generation pain drug fails
Vertex Pharmaceuticals’ longtime chief scientific officer David Altshuler plans to retire next year, the company announced as part of its second-quarter earnings. Vertex also reported major shakeups to...
View ArticleHMNC Brain Health plans Phase 3 for ex-Sanofi depression drug despite...
HMNC Brain Health’s drug has missed the primary endpoint in a Phase 2b depression study designed to show efficacy in a genetically-defined patient subgroup. But the German biotech said its candidate,...
View ArticleAmgen, Lilly can continue fight over alleged improper drug discounts, judge...
Amgen, Eli Lilly and UCB can proceed with a lawsuit that claims HHS improperly certified a string of clinics to receive discounts through the federal 340B program. DC Federal Judge James Boasberg on...
View ArticlePfizer says some tariffs and MFN impact factored in guidance
Pfizer beat revenue expectations in the second quarter and inched up its expected earnings per share for the year, a sign that its yearslong restructuring and pipeline reshuffling effort is starting to...
View ArticleShattuck Labs aims to raise $103M; Beijing biotech gets $55M in Series D
Plus, news about BioMarin and Amneal: Shattuck Labs to raise up to $103M: The inflammatory and immunology specialist said an oversubscribed private placement led by OrbiMed would raise around $46...
View ArticleTrump warns pharma tariffs are coming ‘in the next week or so’
President Donald Trump said pharmaceutical tariffs will be announced as soon as next week and could reach up to 250% after the next year and a half. "We'll be putting initially a small tariff on ...
View ArticleMadrigal's MASH drug handily tops forecasts as execs discuss GLP-1 combos
Madrigal Pharmaceuticals' approved MASH drug could be headed for blockbuster status. Rezdiffra, approved in March 2024 as the first-ever treatment for the fatty liver disease, pulled in ...
View ArticlePfizer CEO says drugmakers are ready to work with Trump on direct sales program
Drugmakers are ready to work with the Trump administration and start direct-to-consumer sales programs, Pfizer CEO Albert Bourla said Tuesday during the company's earnings call. Bourla said he was...
View ArticleBeam delays key AATD readout, reveals plans to dose patients twice
Beam Therapeutics is pushing back a key readout for its alpha-1 antitrypsin deficiency program to next year and testing out a two-dose approach. The company on Tuesday reported an update in ...
View ArticleNovartis' Entresto faces first US generic competitors
Novartis' blockbuster heart drug Entresto is facing its first knockoffs in the US. MSN Pharmaceuticals and Torrent recently completed at-risk launches of their generics as the companies continue to...
View ArticleSpecialty pharma SERB to buy Y-mAbs in $412M all-cash deal
Specialty drugmaker SERB Pharmaceuticals plans to buy cancer biotech Y-mAbs Therapeutics to further broaden its portfolio of more than 70 medicines. SERB will pay $8.60 per share to buy Y-mAbs ...
View ArticleMakary has asked Prasad to 'reconsider' departure from FDA
FDA Commissioner Marty Makary said he wants former CBER head Vinay Prasad to return to the FDA, and said it’s “untrue” that he was pushed out of his role, but instead chose to resign. ...
View ArticleKennedy says BARDA will cancel 22 mRNA vaccine contracts
HHS Secretary Robert F. Kennedy Jr. announced the cancellation or reworking of almost two dozen contracts for the development of mRNA vaccines, including for flu and Covid-19, on Tuesday night. The...
View ArticleAstraZeneca culls plans for Evusheld successor in the US following Covid...
AstraZeneca is no longer seeking FDA approval for its Covid-19 prevention antibody known as sipavibart, a company spokesperson confirmed to Endpoints News. The monoclonal antibody was meant to be a...
View ArticleNovo Nordisk's pipeline cull prompts hopes of strategic shift
Novo Nordisk has cut several programs the day before its new CEO begins. The pipeline pruning could simply be a cost-cutting exercise, and arguably a necessary one following the company’s profit...
View ArticleBayer has laid off 12,000 staffers so far — with more to come
Bayer said its workforce has been reduced by 12,000 employees to date, and anticipates even more job cuts over the next 18 months as it ramps up efforts in its multiyear overhaul. The German...
View ArticleMerck was the only bidder for Verona before the $10B buyout
Verona Pharma spent years courting Merck before the two companies came to terms on the second-largest biotech buyout of the year. There were no other formal bidders during the process, according to new...
View ArticleTerns seeks a partner for its oral metabolic programs; Jazz delays Phase 3...
Plus, news about Roche, Pacira BioSciences, Nxera, Contineum Therapeutics, Astria Therapeutics, Retension Pharmaceuticals, Biomea Fusion, SIGA, Day One and Teva: Terns Pharmaceuticals wants to...
View Article